JNJ vs KPTI
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JNJ shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
KPTI exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -0.50, indicating negative shareholder equity. While the stock has seen a speculative 1-year price surge of 100.5%, the underlying fundamentals are catastrophic with a profit margin of -134.21% and a consistent track record of missing earnings estimates (0/4 in the last year). Despite bullish analyst targets, the combination of insider selling and extreme operational inefficiency suggests a high risk of further capital erosion.
Compare Another Pair
Related Comparisons
JNJ vs KPTI: Head-to-Head Comparison
This page compares Johnson & Johnson (JNJ) and Karyopharm Therapeutics Inc. (KPTI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.